1.31

2.03% -0.03

Telomir Pharmaceuticals Inc (TELO)

Overview News Price History Discussions Forecast

Telomir Pharmaceuticals Inc stock is traded at $1.31, with a volume of 29,225. It is down -2.03% in the last 24 hours and down -15.85% over the past month. Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Previous Close:

$1.34

Open:

$1.31

24h Volume:

29,225

Relative Volume:

0.01

Market Cap:

$45.04M

Revenue:

Net Income/Loss:

$-16.14M

P/E Ratio:

-2.4259

EPS:

-0.54

Net Cash Flow:

$-3.99M

1W Performance:

+3.37%

1M Performance:

-15.85%

6M Performance:

-32.50%

1Y Performance:

-67.02%

1-Day Range:

$1.30

$1.325

1-Week Range:

$1.26

$1.3569

52-Week Range:

$1.12

$7.0791

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name

Telomir Pharmaceuticals Inc

Sector

Healthcare (1137)

Industry

Biotechnology (638)

Phone

786-396-6723

Address

100 SE 2ND ST, MIAMI

Employee

Twitter

Next Earnings Date

2025-12-03

Latest SEC Filings

TELO's Discussions on Twitter

Compare TELO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TELO Telomir Pharmaceuticals Inc	1.31	45.38M	0	-16.14M	-3.99M	-0.54
VRTX Vertex Pharmaceuticals Inc	431.16	110.02B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	777.76	82.00B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	453.38	59.61B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	892.99	56.15B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	206.71	44.31B	447.02M	-1.18B	-906.14M	-6.1812

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-25	Initiated	Rodman & Renshaw	Buy

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

Nov 29, 2025

Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 Chart Watch & Real-Time Volume Triggers - BỘ NỘI VỤ

Nov 29, 2025

Nov 28, 2025

Telomir Pharmaceuticals announces new preclinical data on Telomir-1 - MSN

Nov 28, 2025

Nov 27, 2025

Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support - MarketScreener

Nov 27, 2025

Nov 26, 2025

Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data - MSN

Nov 26, 2025

Nov 25, 2025

Telomir reports PSA reduction in prostate cancer cells with lead drug - Investing.com

Nov 25, 2025

Telomir reports PSA reduction in prostate cancer cells with lead drug By Investing.com - Investing.com South Africa

Nov 25, 2025

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells - The Joplin Globe

Nov 25, 2025

Nov 24, 2025

Telomir Pharmaceuticals Reports Promising Preclinical Data - TipRanks

Nov 24, 2025

[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event | TELO SEC FilingForm 8-K - Stock Titan

Nov 24, 2025

Nov 23, 2025

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells - Bluffton Today

Nov 23, 2025

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death - MSN

Nov 23, 2025

Nov 21, 2025